Shown values refer to:
Figure: Number
Preparation | Year (descending) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
1992 Info | 2000 | 2005 | 2010 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
Specified oral antidiabetics in total | 527.4 | 702.8 | 924.5 | 1,240.3 | 1,314.7 | 1,337.0 | 1,359.8 | 1,477.4 | 1,583.3 | 1,708.6 |
Total specified glibenclamides | 457.6 | 259.9 | 172.1 | 82.6 | 25.4 | 21.4 | 17.9 | 15.3 | 12.7 | 10.8 |
Specified other sulfonylureas altogether | 19.2 | 194.8 | 254.5 | 349.9 | 193.3 | 170.9 | 146.2 | 129.7 | 118.0 | 103.8 |
Gliquidone: Glurenorm | . | . | 3.2 | 3.8 | 1.1 | 0.9 | . | . | . | . |
Specified glinids total | . | 8.3 | 36.5 | 32.9 | 15.7 | 3.8 | 3.3 | 2.8 | 3.0 | 2.6 |
Total specified Metformin | 26.5 | 183.1 | 378.7 | 578.3 | 595.1 | 599.8 | 606.1 | 649.7 | 679.6 | 698.5 |
mentioned Incretinmimetics as a whole | . | . | . | 126.3 | 412.6 | 435.3 | 451.0 | 499.8 | 768.8 | 891.7 |
Specified other oral antidiabetics in total | 24.1 | 56.7 | 79.5 | 66.5 | 71.5 | 106.0 | 135.3 | 180.1 | 229.9 | 298.8 |
The Federal Health Monitoring System 20. Apr 2024